6,105 Hits in 8.7 sec

Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis

Marzio Pennisi, Abdul-Mateen Rajput, Luca Toldo, Francesco Pappalardo
2013 BMC Bioinformatics  
The etiology of the disease is partially understood and the response to treatment cannot easily be predicted.  ...  Conclusions: The presented model allows to capture the essential dynamics of relapsing-remitting MS despite its simplicity.  ...  Acknowledgements The authors would like to thank Prof. Santo Motta for helpful discussions and for suggesting the use of NetLogo framework.  ... 
doi:10.1186/1471-2105-14-s16-s9 pmid:24564794 pmcid:PMC3853330 fatcat:2kwmpthxa5aafgjwoxdvmmoci4

Multiple Sclerosis & Research

Vasiliki E. Kalodimou
2013 Journal of Multiple Sclerosis  
Basic research provides a crucial foundation for innovative approaches to the discovery of effective therapies.  ...  The ability of flow cytometry to estimate cellular DNA content is based on the measurement of fluorescence from dyes which bind in a stoichiometric manner to DNA [6] [7] .  ... 
doi:10.4172/jmso.1000107 fatcat:vvn52xsawbdlzfalopyhuftafi

Multiple Sclerosis & Research

Vasiliki E Kalodimou
2014 Journal of Multiple Sclerosis  
Basic research provides a crucial foundation for innovative approaches to the discovery of effective therapies.  ...  The ability of flow cytometry to estimate cellular DNA content is based on the measurement of fluorescence from dyes which bind in a stoichiometric manner to DNA [6] [7] .  ... 
doi:10.4172/2376-0389.1000107 fatcat:euomp2eufzhnnjqycqx32w4l5i

Personalised medicine for multiple sclerosis care

Arie Gafson, Matt J Craner, Paul M Matthews
2016 Multiple Sclerosis  
Abstract Background Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS).  ...  Models that explain data are not enough: to be clinically useful, models also need to be able to predict future outcomes for individuals in a quantitative framework that can provide a basis for joint decision  ... 
doi:10.1177/1352458516672017 pmid:27672137 fatcat:67jzvgzqazevdha4jit34zdboq

Multiple sclerosis—a quiet revolution

Richard M. Ransohoff, David A. Hafler, Claudia F. Lucchinetti
2015 Nature Reviews Neurology  
Multiple sclerosis (MS) has been thought to be a complex and indecipherable disease, and poorly understood with regards to aetiology.  ...  Here we focus on MS therapeutics-the most meaningful outcome of research efforts.  ...  with MS is undergoing a rapid transition, moving from the routine use of earlier first era therapies to a more rational approach based on effectiveness versus safety and tolerability.  ... 
doi:10.1038/nrneurol.2015.14 pmid:25686758 pmcid:PMC4556342 fatcat:4rzuqhdydbehdhclcjcsyrquni

Multiple Sclerosis [chapter]

Dimitrios Karussis
2017 International Encyclopedia of Public Health  
Acknowledgment The author would like to thank Dr Panayiota Petrou for her great help and contribution in the writing and reviewing of this manuscript.  ...  of Multiple Sclerosis Centers (CMSC) to evaluate patients presenting with possible CIS .  ...  Therapy of MS Logically, based on this widely accepted model for MS immunopathogenesis described previously (Tables 2 and 3; Figure 3a ), the therapeutic approaches to the disease include modalities aimed  ... 
doi:10.1016/b978-0-12-803678-5.00295-2 fatcat:yzmpj2tz6fgkrmjabh6li5fj4a

Multiple sclerosis

David A. Hafler
2004 Journal of Clinical Investigation  
Acknowledgments The author wishes to thank all of the present and past laboratory members and colleagues for so many of the ideas and concepts used in this article.  ...  In particular, I would like to acknowledge Amit Bar-Or, Kevin O'Connor, John Rioux, and Phil De Jager who provided specific assistance, and my long-term partnerships with Howard Weiner, Samia Khoury, and  ...  or in predicting outcome is still not well defined.  ... 
doi:10.1172/jci21357 pmid:15067307 pmcid:PMC362131 fatcat:if7zouu7tzesve5263h6hv3hum

Multiple Sclerosis

Daniel S. Reich, Claudia F. Lucchinetti, Peter A. Calabresi, Dan L. Longo
2018 New England Journal of Medicine  
Pathology The pathological conception of MS as a disseminated "plaque-like sclerosis" was established ~150 years ago; indeed, the demonstration of dissemination -in space (diseaserelated changes in multiple  ...  Our understanding of the details of that pathology, and especially how it evolves over time,  ...  Figure 1 . 1 Topography of multiple sclerosis lesions.  ... 
doi:10.1056/nejmra1401483 pmid:29320652 pmcid:PMC6942519 fatcat:snpigfocifexrkhvlvdczroivu

Multiple Sclerosis Management – A Changing Landscape 2013

Per Soelberg Sørensen, Massimo Filippi, Wolfgang Brück
2013 European Neurological Review  
The aims of this educational meeting, held in Vienna, Austria, were to explore the significant advances that have occurred in multiple sclerosis (MS) management over the past two decades, to highlight  ...  modern-day perspectives and challenges and to consider the impact of the new oral first-line treatments expected to enter the MS market shortly.  ...  Insights and Challenges for Modern Multiple Sclerosis Management The Advent of Oral Multiple Sclerosis Agents Mechanism of Action of Oral Agents for Multiple Sclerosis Wolfgang Brück (Gottingen, Germany  ... 
doi:10.17925/enr.2013.08.02.105 fatcat:3enycppnmbgunl3m5eqns3ybae

Risk stratification and mitigation in multiple sclerosis

Daniel Ontaneda, Samuel Cohn, Robert J. Fox
2014 Multiple Sclerosis and Related Disorders  
The increasing availability of new agents to treat multiple sclerosis poses new challenges for clinicians who seek therapies that are both safe and effective for their patients.  ...  In this review we present risk stratification and mitigation strategies of disease modifying agents for multiple sclerosis.  ...  The International Campath-1H in Multiple Sclerosis trial (CAMMS223) found alemtuzumab to be effective at reducing relapse rates, slowing progression of disability, and improving MRI outcomes in patients  ... 
doi:10.1016/j.msard.2014.05.003 pmid:25221744 pmcid:PMC4159169 fatcat:7unjhpvujzg7nffpfwmtohzuz4

Multiple sclerosis

Sharon G. Lynch, John W. Rose
1996 Disease-a-month  
Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature.  ...  Treatment is based on general supportive care, the use of corticosteroids for relapses, and symptomatic management of ongoing problems.  ...  Treatment of relapses is recommended for moderate to severe relapses. Corticosteroids are choice of treatment of relapses.  ... 
doi:10.1016/s0011-5029(96)90012-7 pmid:8556963 pmcid:PMC7130340 fatcat:tnykp4vvxresrl4maouvzyhyim

Regular review: Drug treatment of multiple sclerosis

C H Polman
2000 BMJ (Clinical Research Edition)  
The ability to predict the development of disability in a disease as variable as multiple sclerosis is a major challenge.  ...  5 Treatment The possibilities for treatment of multiple sclerosis depend on the clinical situation.  ... 
doi:10.1136/bmj.321.7259.490 pmid:10948033 pmcid:PMC1118391 fatcat:eapd3t5in5a35hkylwxwzhnzo4

Optimizing treatment success in multiple sclerosis

Tjalf Ziemssen, Tobias Derfuss, Nicola de Stefano, Gavin Giovannoni, Filipe Palavra, Davorka Tomic, Tim Vollmer, Sven Schippling
2015 Journal of Neurology  
Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the introduction of several disease-modifying therapies (DMTs), the burden of progressive disability and premature  ...  Together, the advent of new MS therapies and evolving management strategies offer exciting new opportunities to optimize treatment outcomes.  ...  The key outcomes from this meeting are summarized in this paper. Monitoring disease activity in multiple sclerosis Monitoring MS disease activity is key to achieving optimal outcomes.  ... 
doi:10.1007/s00415-015-7986-y pmid:26705122 pmcid:PMC4893374 fatcat:434et6ovo5fwjjndpdyszdrgcq

The future of multiple sclerosis treatments

Catalina Coclitu, Cris S. Constantinescu, Radu Tanasescu
2016 Expert Review of Neurotherapeutics  
There are not many conditions in which the last few decades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS).  ...  A note on versions: The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version.  ...  Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al.  ... 
doi:10.1080/14737175.2016.1243056 pmid:27682738 fatcat:chrfcspesrcczftbueqswstpqe

ACTRIMS-ECTRIMS MSBoston 2014: Oral Presentations

2014 Multiple Sclerosis  
TC2.2 Choosing the right treatment for the right patient RJ Fox 1 Despite few head-to-head comparison treatment trials, the comparability of many long-term MS disease modifying agents is emerging, which  ...  Risk mitigation includes assessments prior to treatment initiation and over the course of treatment.  ...  Because relapses are more likely to cause permanent disability in NMO than in MS, time to relapse may be a more suitable outcome in NMO than relapse rate.  ... 
doi:10.1177/1352458514547850 pmid:25205046 pmcid:PMC4244174 fatcat:slfrrcwtozbfldgoio6kgacvgm
« Previous Showing results 1 — 15 out of 6,105 results